Separate and Combined Extrapancreatic Effects of GIP and GLP-1

NCT06895408 · Completed

Last updated 2026-05-28

This clinical trial is testing how gut hormones GIP and GLP-1 separately and together affect blood sugar levels in people who have had their pancreas removed.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 12 people

Who can join Ages 30–75 · all sexes

Timeline Started 2025-02 · est. completion 2025-07

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT06895408 ↗

Description as written by the study sponsor.

The two gut-derived hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are secreted from intestinal cells in relation to a meal and increase insulin secretion from the pancreas. The hormones also exert effects outside the pancreas, but especially for GIP, these are poorly investigated. Because of this, only GLP-1 based drugs (GLP-1 receptor agonists) are on the market for the treatment of type 2 diabetes and obesity. Nonetheless, a new drug is in clinical development: a combined GIP-GLP-1-receptor agonist (tirzepatide), which has shown better results than GLP-1 alone. The mechanism behind these impressive effects are unknown and in this study, the investigators will look into the exptrapancreatic effects of GIP and GLP-1, separate and combined and thus elucidate the mechanisms of action of this new drug class.

Treatments tested

Intravenous Infusion Other

Glucose-dependent Insulinotropic Polypeptide
Intravenous Infusion Other

Glucagon-Like Peptide 1
Intravenous Infusion Other

Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide 1
Intravenous Infusion Other

Saline

Main thing measured	Plasma glucose
Sponsor	University Hospital, Gentofte, Copenhagen
Conditions studied	Pancreatectomy; Hyperglycemia
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06895408 ↗